Tarlatamab – a new SoC in 2L SCLC

9 hours ago
MIMS Editorial Team
MIMS Editorial Team
MIMS Editorial Team
MIMS Editorial Team

After decades of topotecan being the sole standard second-line (2L) treatment for small-cell lung cancer (SCLC) in most countries, tarlatamab’s efficacy and a favourable safety and tolerability profile vs chemotherapy (CT) have defined a new standard of care (SoC) for patients whose disease progressed on or after initial platinum-based CT, according to Dr Martin Wermke of the National Center for Tumor Diseases Dresden Early Clinical Trial Unit in Dresden, Germany, who spoke at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Topotecan: Better than nothing, comparable to other CTs

Almost all patients with SCLC relapse after achieving a complete response to first-line (1L) treatment. Their prognosis is poor, with a median survival of 2–3 months without further treatment and approximately 6 months in case of response to 2L therapy. [Cancers (Basel) 2024;16:255]

The first randomized phase III trial to evaluate 2L options in SCLC compared topotecan (n=107) and cyclophosphamide, doxorubicin and vincristine (CAV) (n=104) in patients who relapsed ≥60 days after completion of 1L therapy. The response rates were 24.3 vs 18.3 percent, respectively, while median time to progression was 13.3 vs 12.3 weeks and median survival was 25.0 vs 24.7 weeks. It was concluded that topotecan was at least as effective as CAV. The proportion of patients with symptom improvement was greater in the topotecan vs CAV group for some of the symptoms evaluated, including dyspnoea, anorexia, hoarseness, and fatigue, as well as interference with daily activity (p≤0.043). [J Clin Oncol 1999;17:658-667]

Another randomized phase III trial compared oral topotecan with supportive care alone in 141 patients who experienced progression after 1L treatment and were deemed unsuitable for intravenous treatment. Oral topotecan resulted in a significant increase in overall survival (OS; 25.9 vs 13.9 weeks; p=0.0104), a slower deterioration of quality of life, and better symptom control vs supportive care, at the cost of haematological toxicity (grade 4 neutropenia, 33 percent; grade 4 thrombocytopenia, 7 percent; grade 3/4 anaemia, 25 percent). [J Clin Oncol 2006;24:5441-5447]

“Topotecan beats nothing, but at a price,” remarked Wermke.

A phase III randomized trial compared amrubicin, a synthetic anthracycline, with topotecan in 673 patients with SCLC sensitive or refractory to 1L treatment. While reporting a better response rate of 31 vs 17 percent, it did not find an OS benefit (7.5 vs 7.8 months) with amrubicin in the overall population. [J Clin Oncol 2014;32:4012-4019]

Lurbinectedin, a synthetic alkylating agent, in combination with doxorubicin (n=307) was compared against the control of topotecan (n=127) or CAV (n=179) in a phase III, open-label, randomized study in patients with SCLC who relapsed after 1L platinum-based CT. Median OS was 8.6 vs 7.6 months in the lurbinectedin plus doxorubicin vs control group, but the difference failed to reach statistical significance. [Lancet Respir Med 2023;11:74-86] Another phase III trial evaluating lurbinectedin plus irinotecan vs topotecan or irinotecan also did not meet its primary endpoint of OS. [https://investor.jazzpharma.com/node/22966/pdf]

A new approach with DLL3-targeting agents

Delta-like ligand 3 (DLL3), a Notch inhibitory ligand that promotes cell proliferation and survival, is an attractive therapeutic target because it is specifically overexpressed on the surface of SCLC cells, with minimal to no expression on normal cells. [J Hematol Oncol 2023;16:66]

DLL3-directed T-cell engagers have exhibited encouraging initial efficacy and safety profiles in early clinical studies of patients with relapsed/refractory SCLC. “Phase I trials have shown similar activity across tarlatamab [n=107] [objective response rate (ORR), 23 percent; median duration of response (DoR), 12.3 months], obrixtamig [n=168] [overall response rate, 23 percent; median DoR, 8.5 months] and gocatamig [SCLC, n=39; other neuroendocrine cancers, n=34] [confirmed ORR, 44 percent],” reported Wermke. [J Clin Oncol 2023;doi:10.1200/JCO.22.02823; J Clin Oncol 2025;10.1200/JCO-25-00363; Beltran H, et al, ESMO 2025, abstract 2758MO]

DeLLphi-304: Longer OS, fewer AEs grade ≥3, favourable PROs with tarlatamab vs CT

DeLLphi-304 was a multinational, phase III, open-label trial that compared tarlatamab (n=254; median age, 64 years) vs CT (n=255) as 2L treatment in patients with SCLC whose disease had progressed during or after platinum-based CT. Among the patients in the CT group, 73 percent were assigned to receive topotecan, 18 percent to lurbinectedin, and 9 percent to amrubicin.

The median age of patients was 65 years. Most patients were male (66–72 percent), former smokers (68–70 percent), have received prior PD-L1 or PD-1 inhibitor therapy (71 percent), and had no brain (55–56 percent) or liver (63–67 percent) metastases. Asian patients accounted for 38 percent in the tarlatamab arm and 42 percent in the CT arm. [Engl J Med 2025;393:349-361]

Efficacy

At a median follow-up of 11.2 months in the tarlatamab group and 11.7 months in the CT group, the median OS was 13.6 vs 8.3 months (stratified hazard ratio [HR], 0.60; 95 percent confidence interval [CI], 0.47–0.77; p<0.001). The 6- and 12-month OS rates were 76 vs 62 percent and 53 vs 37 percent, respectively. “The OS benefit was observed in all subgroups,” noted Wermke.

The median PFS was 4.2 months in the tarlatamab group and 3.7 months in the CT group. Estimated 6- and 12-month PFS rates were 31 vs 23 percent and 20 vs 4 percent, respectively.

The confirmed ORR was 35 percent with tarlatamab vs 20 percent with CT (risk ratio, 1.73; 95 percent CI, 1.29–2.33). The median time to response was 1.5 vs 1.4 months, while median DoR was 6.9 vs 5.5 months. The 12-month duration of response estimate was 41 and 13 percent for the respective groups.

Safety

Treatment-related adverse events (TRAEs) of grade ≥3 occurred in 27 vs 62 percent of patients in the tarlatamab vs CT group. The most common grade ≥3 TRAEs with tarlatamab included neutropenia, lymphopenia, lymphocyte count decrease, fatigue, neutrophil count decrease, hyponatraemia, and anaemia, which occurred in 2–4 percent of patients. In the CT group, the most common grade ≥3 TRAEs were anaemia, neutropenia, leukopenia, febrile neutropenia, thrombocytopenia, and neutrophil count decrease, which were reported in 11–28 percent of patients.

Serious TRAEs occurred in 28 vs 31 percent of patients on tarlatamab vs CT. TRAEs led to dose interruption, dose reduction, or both in 19 vs 55 percent of the patients, and to treatment discontinuation in 3 vs 6 percent of patients, respectively. TRAEs resulted in death (according to investigator assessment) in one patient in the tarlatamab group and in four patients in the CT group.

Cytokine release syndrome (CRS) occurred in 56 percent of patients in the tarlatamab group. Most CRS events were of grade 1 (42 percent) or grade 2 (13 percent), and occurred primarily after receipt of one of the first two doses of tarlatamab. Most events resolved with supportive care alone. Glucocorticoids were administered for CRS in 16 percent of patients. Additional interventions included tocilizumab in 4 percent of patients, supplemental oxygen in 8 percent, and vasopressor support in <1 percent.

Neurologic AEs occurred in 56 vs 35 percent of patients on tarlatamab vs CT. Dysgeusia was the most common neurologic event in the tarlatamab group, with an incidence of 24 percent vs 2 percent in CT group. Neurologic events of grade ≥3 occurred in 4 vs 6 percent of patients. Immune effector cell–associated neurotoxicity syndrome occurred in 6 percent of patients on tarlatamab and were predominantly of grade 1–2, with the exception of one grade 5 event, which led to a patient’s death.

Patient-reported outcomes

Compared with CT, tarlatamab improved cancer-related symptoms of dyspnoea and cough. The prespecified analyses of patient-reported changes at week 19 found that treatment with tarlatamab resulted in significantly greater decreases in symptom scores vs CT in dyspnoea (mean between-group difference, -9.14 points; p<0.001) and cough (odds ratio, 2.04; 95 percent CI, 1.17–3.55; p=0.01), while the between-group difference in the change from baseline was not significant for chest pain score.

Conclusion

Collectively, the survival benefit, predominantly low-grade toxic effects, and favourable patient-reported outcomes (PROs) support the use of tarlatamab for SCLC that has progressed during or after initial platinum-based CT.

“After decades with little progress in 2L treatment of SCLC, there is finally a new champion,” concluded Wermke.